ASCO 2022 Conference Coverage


 

Lecture Summary - ASCO 2022 Nivolumab + Relatlimab vs. Nivo in 1L Metastatic/Unresectable Melanoma: OS & ORR by Key Subgroups From the RELATIVITY-047

18 views
June 9, 2022
Comments 0
Login to view comments. Click here to Login